Courier Capital LLC Sells 13,119 Shares of AbbVie Inc. $ABBV

Courier Capital LLC trimmed its position in shares of AbbVie Inc. (NYSE:ABBV) by 82.6% during the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 2,756 shares of the company’s stock after selling 13,119 shares during the quarter. Courier Capital LLC’s holdings in AbbVie were worth $721,000 at the end of the most recent reporting period.

Other hedge funds also recently modified their holdings of the company. State Street Corp boosted its holdings in shares of AbbVie by 1.7% in the 2nd quarter. State Street Corp now owns 82,596,748 shares of the company’s stock worth $20,784,646,000 after acquiring an additional 1,379,232 shares in the last quarter. Corient Private Wealth LP bought a new stake in AbbVie during the 2nd quarter worth approximately $559,736,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in AbbVie by 0.7% during the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock worth $3,590,323,000 after acquiring an additional 106,091 shares during the last quarter. Legal & General Group Plc acquired a new stake in AbbVie during the 2nd quarter valued at $2,905,952,000. Finally, Deutsche Bank AG increased its holdings in AbbVie by 13.0% during the 2nd quarter. Deutsche Bank AG now owns 10,772,949 shares of the company’s stock valued at $2,710,905,000 after purchasing an additional 1,241,587 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Potential third-quarter revenue beat: RBC expects AbbVie to exceed top-line estimates, driven by continued momentum in Skyrizi, Rinvoq and Vraylar. The outlook reinforces the company’s ability to offset ongoing Humira erosion ahead of its quarterly results. AbbVie Poised for Q3 Top-Line Beat Driven by Rinvoq, Skyrizi, and Vraylar Therapies, RBC Says
• Positive Sentiment: Encouraging Skyrizi data: New Phase 3 AFFIRM results showed favorable clinical and endoscopic outcomes for subcutaneous Skyrizi in patients with moderately to severely active Crohn’s disease. The data could support broader use of the therapy and strengthen AbbVie’s post-Humira growth strategy. AbbVie Presents New Phase 3 AFFIRM Data
• Positive Sentiment: Pipeline and franchise expansion: Recent Skyrizi and Rinvoq data presented at ACG 2026, along with new oncology designations and early metabolic-program results, are broadening the investment case beyond immunology. Analysts also point to a recently completed acquisition and a fresh FDA approval as potential future growth drivers. AbbVie Highlights Long-Term SKYRIZI, RINVOQ Data Findings
• Positive Sentiment: Analyst support: Royal Bank of Canada reaffirmed its “Outperform” rating and set a $280 price target, while broader commentary describes AbbVie’s pipeline as potentially undervalued. The stock also remains attractive to income-focused investors because of its dividend profile. RBC Reaffirms AbbVie Outperform Rating
• Neutral Sentiment: Investor debate continues: Comparisons with Eli Lilly highlight AbbVie’s steadier diversification through Skyrizi and Rinvoq versus Lilly’s faster cardiometabolic growth, leaving investors divided over relative upside.
• Negative Sentiment: Key risks remain: Humira sales continue to decline, immunology competition is increasing, and AbbVie’s elevated valuation leaves less room for disappointing results or weaker guidance.

AbbVie Trading Down 2.2%

Shares of AbbVie stock traded down $6.30 during midday trading on Tuesday, reaching $274.82. The company had a trading volume of 6,408,343 shares, compared to its average volume of 6,414,627. The company has a market capitalization of $485.55 billion, a price-to-earnings ratio of 77.63, a price-to-earnings-growth ratio of 1.26 and a beta of 0.24. The stock has a fifty day simple moving average of $259.79 and a 200 day simple moving average of $237.39. AbbVie Inc. has a 1-year low of $190.75 and a 1-year high of $283.43.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping the consensus estimate of $3.61 by $0.04. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. The firm had revenue of $16.99 billion during the quarter, compared to analysts’ expectations of $16.80 billion. During the same quarter in the previous year, the company posted $2.97 EPS. AbbVie’s revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Sell-side analysts expect that AbbVie Inc. will post 13.94 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Stockholders of record on Thursday, October 15th will be paid a $1.73 dividend. This represents a $6.92 annualized dividend and a dividend yield of 2.5%. The ex-dividend date of this dividend is Thursday, October 15th. AbbVie’s dividend payout ratio (DPR) is 195.48%.

Wall Street Analyst Weigh In

ABBV has been the subject of several research analyst reports. Oppenheimer lifted their price objective on AbbVie from $244.00 to $258.00 and gave the company a “neutral” rating in a research report on Monday, August 3rd. Argus increased their target price on AbbVie from $250.00 to $270.00 in a report on Tuesday, August 4th. JPMorgan Chase & Co. raised their target price on AbbVie from $285.00 to $300.00 and gave the company an “overweight” rating in a research note on Thursday, October 8th. Wolfe Research raised AbbVie from a “peer perform” rating to an “outperform” rating and lifted their price target for the company from $235.00 to $300.00 in a report on Thursday, August 13th. Finally, Piper Sandler upped their price target on shares of AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $277.18.

Insider Buying and Selling at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the completion of the sale, the executive vice president owned 74,430 shares in the company, valued at $18,607,500. The trade was a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.06% of the stock is currently owned by insiders.

AbbVie Company Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.